Literature DB >> 7227714

Antitumor activity of platinum(II) complexes of 1,2-diamino-cyclohexane isomers.

Y Kidani, M Noji, T Tashiro.   

Abstract

Dichloro, dibromo, oxalato, malonato, dinitrato, sulfato and mono and bis-(D-glucuronato) platinum(II) complexes of 1,2-diaminocyclohexane (dach) isomers were prepared and tested on L1210 mouse leukemia employing the NCI protocol for evaluation of Pt analogs. A large number of long-term survivors were observed with certain analogs, though the therapeutic indices (optimal dose/minimum effective dose) were not large. Among the analogs tested, the oxalato, malonato, dinitrato and mono-(D-glucuronato) Pt(II) complexes of trans-1,2-diaminocyclohexane were found to be particularly effective. The glucuronato Pt complexes appear to be promising candidates for clinical trial since they have the highest solubility in water.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7227714

Source DB:  PubMed          Journal:  Gan        ISSN： 0016-450X


  21 in total

1.  Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines.

Authors:  T A Dunn; H J Schmoll; V Grünwald; C Bokemeyer; J Casper
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

2.  A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia.

Authors:  Apostolia Maria Tsimberidou; Michael J Keating; Elias J Jabbour; Farhad Ravandi-Kashani; Susan O'Brien; Elihu Estey; Neby Bekele; William K Plunkett; Hagop Kantarjian; Gautam Borthakur
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-02-03

Review 3.  DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment.

Authors:  S Solier; Y-W Zhang; A Ballestrero; Y Pommier; G Zoppoli
Journal:  Curr Cancer Drug Targets       Date:  2012-05       Impact factor: 3.428

Review 4.  Oxaliplatin: pharmacokinetics and chronopharmacological aspects.

Authors:  F Lévi; G Metzger; C Massari; G Milano
Journal:  Clin Pharmacokinet       Date:  2000-01       Impact factor: 6.447

5.  Phase I study of oxaliplatin in patients with advanced cancer.

Authors:  J M Extra; M Espie; F Calvo; C Ferme; L Mignot; M Marty
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 6.  New cisplatin analogues in development. A review.

Authors:  Raymond B Weiss; Michaele C Christian
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

7.  Phase-II trial of 1,2-diaminocyclohexane (4-carboxyphthalato) platinum (II) (DACCP) in non-small cell lung cancer.

Authors:  H I Scher; D Kelsen; L Kalman; L Jones; J Burchenal; R Gralla
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

8.  Pharmacokinetics of (1R,2R-diaminocyclohexane)oxalatoplatinum(II) in comparison with cisplatin following a single intravenous injection in rabbits.

Authors:  R Kizu; S Higashi; Y Kidani; M Miyazaki
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 9.  Unusual DNA binding modes for metal anticancer complexes.

Authors:  Ana M Pizarro; Peter J Sadler
Journal:  Biochimie       Date:  2009-04-01       Impact factor: 4.079

10.  Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome.

Authors:  Apostolia M Tsimberidou; William G Wierda; Sijin Wen; William Plunkett; Susan O'Brien; Thomas J Kipps; Jeffrey A Jones; Xavier Badoux; Hagop Kantarjian; Michael J Keating
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.